LITIMIC
Live / Allowed — Published for opposition (as of 23 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 01 May 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99165165
- Mark type
- Stylized text
- Filed
- 01 May 2025
- Published for opposition
- 11 Nov 2025
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; Anti-infectives; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiopulmonary, genitourinary, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 22 Mar 2026 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 11 Mar 2026 — POST PUBLICATION AMENDMENT - ENTERED
- 08 Mar 2026 — ASSIGNED TO PETITION STAFF
- 12 Jan 2026 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 11 Dec 2025 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 11 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Nov 2025 — PUBLISHED FOR OPPOSITION
- 05 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 15 Sept 2025 — ASSIGNED TO EXAMINER
- 01 May 2025 — APPLICATION FILING RECEIPT MAILED
- 01 May 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 01 May 2025 — NEW APPLICATION ENTERED